Shawn Manchester

This inventor holds 20 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 3 EPO patents, primarily in Genomic Engineering. Top assignee: Zymergen Inc.. Active years: 2018-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shawn Manchester. Retrieved from https://idiyas.com/inventor/shawn-manchester

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 6)

% Patents Active = 90.0

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 5.0

ph-index = 7

Forward Citations = 242(Granted Patents)

Company Filing History:

20 out of 57

Zymergen Inc.

patents

Years Active: 2018-2023

Loading Chart...

Areas of Expertise:

Genetic Perturbation

RNA Degradosome

NADPH

Biosynthetic Pathways

Host Cell Improvement

Epistatic Effects

Automated Systems

Microbial Strain Improvement

Bacterial Hemoglobin Library

Glucose Permease Library

HTP Genomic Engineering

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11549096 - Genetic perturbation of the RNA degradosome protein complex (2023-01-10),

2. 11519012 - Genomic engineering of biosynthetic pathways leading to increased NADPH (2022-12-06),

3. 11352621 - HTP genomic engineering platform (2022-06-07),

4. 11312951 - Systems and methods for host cell improvement utilizing epistatic effects (2022-04-26),

5. 11293029 - Promoters from (2022-04-05),

6. 11208649 - HTP genomic engineering platform (2021-12-28),

7. 11155808 - HTP genomic engineering platform (2021-10-26),

8. 11155807 - Automated system for HTP genomic engineering (2021-10-26),

9. 11085040 - Systems and methods for host cell improvement utilizing epistatic effects (2021-08-10),

10. 10968445 - HTP genomic engineering platform (2021-04-06),

11. 10883101 - Automated system for HTP genomic engineering (2021-01-05),

12. 10808243 - Microbial strain improvement by a HTP genomic engineering platform (2020-10-20),

13. 10745694 - Automated system for HTP genomic engineering (2020-08-18),

14. 10647980 - Microbial strain improvement by a HTP genomic engineering platform (2020-05-12),

15. 10544411 - Methods for generating a glucose permease library and uses thereof (2020-01-28),

Title: Profile of Inventor Shawn Manchester: Pioneering Innovations in Genetic Engineering

Introduction: Shawn Manchester, based in Oakland, CA, is an accomplished inventor with a remarkable portfolio of 20 patents. His innovative work primarily focuses on genetic engineering and microbial strains, paving the way for advancements in biotechnology and synthetic biology.

Latest Patents: Shawn's latest patents showcase his cutting-edge research and contributions to the field. One such patent is titled "Genetic perturbation of the RNA degradosome protein complex," which introduces novel bacterial strains with modifications in RNA degradation and processing genes. This invention provides methods for generating microbial strains with heterologous promoter sequences that enhance RNA regulation.

Another significant patent is "Genomic engineering of biosynthetic pathways leading to increased NADPH." This patent discusses host cells engineered to alter NADPH availability, facilitating the enhanced production of various compounds. The methods involved include expressing variants of key enzymes like GAPDH and glutamate dehydrogenase, among others, to optimize biochemical pathways.

Career Highlights: As a key member of Zymergen Inc., Shawn has contributed significantly to the company's mission of leveraging biotechnology to drive sustainable innovation. His extensive research and development efforts have established him as a leading inventor in the industry.

Collaborations: Shawn has worked alongside talented colleagues, including Katherine Gora and Erik Jedediah Dean. Their collaborative efforts have propelled advancements in genetic engineering and have continued to push the boundaries of microbial biotechnology.

Conclusion: Shawn Manchester's inventive spirit and dedication to advancing genetic engineering through his patents underscore his vital role in the field of biotechnology. As he continues to innovate at Zymergen Inc., his contributions will undoubtedly shape the future of synthetic biology and sustainable practices.

Profile summary based on public USPTO records.